Chugai Pharmaceutical Co., Ltd. Share Price
Stocks
4519
JP3519400000
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
02:51:42 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6,968.00 JPY | +0.80% |
|
-0.26% | -15.46% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-18 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 11,374B 71.2B 61.3B 57.56B 52.54B 98.7B 6,774B 99.41B 682B 265B 3,435B 267B 262B | P/E 2026 * |
22.4x | P/E 2027 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise Value | 10,464B 65.5B 56.39B 52.95B 48.34B 90.81B 6,232B 91.46B 627B 244B 3,160B 246B 241B | EV / Sales 2026 * |
7.54x | EV / Sales 2027 * | 6.68x |
| Free-Float |
38.12% | Yield 2026 * |
1.97% | Yield 2027 * | 2.25% |
Last Transcript : Chugai Pharmaceutical Co., Ltd.
| 1 day | +0.81% | ||
| 1 week | -0.26% | ||
| Current month | +0.53% | ||
| 1 month | +0.53% | ||
| 3 months | -9.07% | ||
| 6 months | -29.41% | ||
| Current year | -15.46% |
| 1 week | 6,855 |  | 7,090 |
| 1 month | 6,575 | | 7,229 |
| Current year | 6,575 | | 10,700 |
| 1 year | 6,250 | | 10,700 |
| 3 years | 4,197 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 28/02/2021 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 27/03/2024 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 29/02/2020 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 27/03/2024 |
| Director/Board Member | 51 | 28/02/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.80% | -0.26% | +6.89% | +56.36% | 72.33B | |
| -1.52% | -7.23% | +57.90% | +108.72% | 1,047B | |
| -0.82% | -2.63% | +50.05% | +64.43% | 646B | |
| +0.37% | -3.06% | +21.87% | +74.48% | 451B | |
| -1.64% | -4.75% | +35.59% | +35.54% | 355B | |
| -0.39% | -2.76% | +21.39% | +38.01% | 291B | |
| -1.19% | -2.21% | +1.53% | +11.51% | 252B | |
| -0.59% | -3.15% | +49.83% | +67.70% | 234B | |
| -1.05% | -2.29% | -19.91% | -54.10% | 203B | |
| +0.45% | -0.27% | +29.84% | +91.34% | 181B | |
| Average | -0.56% | -2.59% | +25.50% | +49.40% | 373.16B | |
| Weighted average by Cap. | -0.85% | -3.86% | +36.33% | +64.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.69B 7.48B 7.03B 6.41B 12.05B 827B 12.13B 83.25B 32.39B 419B 32.63B 31.92B | 1,529B 9.57B 8.24B 7.74B 7.06B 13.27B 911B 13.37B 91.71B 35.68B 462B 35.95B 35.16B |
| Net income | 507B 3.17B 2.73B 2.57B 2.34B 4.4B 302B 4.43B 30.4B 11.83B 153B 11.91B 11.65B | 585B 3.66B 3.15B 2.96B 2.7B 5.08B 349B 5.12B 35.1B 13.66B 177B 13.76B 13.46B |
| Net Debt | -910B -5.7B -4.91B -4.61B -4.2B -7.9B -542B -7.95B -54.58B -21.23B -275B -21.39B -20.93B | -1,151B -7.2B -6.2B -5.82B -5.32B -9.99B -685B -10.06B -69.01B -26.85B -348B -27.05B -26.46B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/09/26 | JP¥6,968.00 | +0.80% | 587,700 |
| 31/08/26 | JP¥6,913.00 | -1.71% | 2,937,400 |
| 28/08/26 | JP¥7,033.00 | +1.24% | 1,982,400 |
| 27/08/26 | JP¥6,947.00 | -1.47% | 1,806,300 |
| 26/08/26 | JP¥7,051.00 | +1.45% | 1,503,700 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
